BCAL Diagnostics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
BCAL Diagnostics's earnings have been declining at an average annual rate of -44.4%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 55% per year.
Información clave
-44.4%
Tasa de crecimiento de los beneficios
-34.1%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 9.6% |
| Tasa de crecimiento de los ingresos | 55.0% |
| Rentabilidad financiera | -74.5% |
| Margen neto | -206.6% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastos
Cómo gana y gasta dinero BCAL Diagnostics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -6 | 4 | 4 |
| 31 Mar 24 | 3 | -6 | 4 | 4 |
| 31 Dec 23 | 4 | -5 | 4 | 4 |
| 30 Sep 23 | 3 | -5 | 3 | 4 |
| 30 Jun 23 | 3 | -5 | 3 | 4 |
| 31 Mar 23 | 2 | -5 | 3 | 4 |
| 31 Dec 22 | 1 | -5 | 2 | 3 |
| 30 Sep 22 | 1 | -4 | 2 | 3 |
| 30 Jun 22 | 1 | -3 | 2 | 2 |
| 31 Mar 22 | 1 | -3 | 1 | 2 |
| 31 Dec 21 | 1 | -3 | 1 | 2 |
| 30 Sep 21 | 0 | -2 | 1 | 1 |
| 30 Jun 21 | 0 | -2 | 1 | 1 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 1 | 0 | 1 | 0 |
| 30 Sep 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 1 | 0 |
| 30 Jun 19 | 0 | 0 | 0 | 0 |
| 30 Jun 18 | 0 | 0 | 0 | 0 |
Ingresos de calidad: BDX is currently unprofitable.
Margen de beneficios creciente: BDX is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: BDX is unprofitable, and losses have increased over the past 5 years at a rate of 44.4% per year.
Acelerando crecimiento: Unable to compare BDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: BDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).
Rentabilidad financiera
Alta ROE: BDX has a negative Return on Equity (-74.52%), as it is currently unprofitable.